People in England to benefit from groundbreaking one-off gene therapy for severe sickle cell disease approved by NICE ...

The treatment is recommended for people aged 12 to 65 who have moderate to severe and persistent allergic rhinitis and have been diagnosed through clinical history and a positive test of their house ...

This indicator covers the incidence of healthcare associated infections from Methicillin-resistant Staphylococcus aureus (MRSA). It measures outcomes that reflect the quality of care or processes ...

This indicator covers under 75 mortality from respiratory disease. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator will be ...

This indicator will be reviewed using the assessment criteria in appendix B of the NICE indicators process guide when it reaches its review date or the underlying guidance is updated.

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

For a short explanation of why the committee made this recommendation for research, see the rationale section on treatment strategies for non-proliferative and proliferative diabetic retinopathy .

For a short explanation of why the committee made this recommendation for research, see the rationale section on information that should be available to all people involved in the care of people with ...

What are the clinical features or factors that suggest treatment should be switched or stopped for people with diabetic macular oedema? For a short explanation of why the committee made this ...

In people experiencing a rapid, substantial reduction in HbA1c, what is the risk of short-term progression of diabetic retinopathy or diabetic macular oedema, and is there a risk of long-term visual ...

Suggested remit: To appraise the clinical and cost effectiveness of pembrolizumab with olaparib within its marketing authorisation as maintenance treatment of advanced squamous non-small-cell lung ...

Please note that following on from information provided to NICE by the company in Dec 2023 , the appraisal was suspended from NICE’s work programme. As no further information has been received from ...